Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Daiichinkyo Co's share price for the quarter that ended in Mar. 2024 was 円4759. Daiichinkyo Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1,918 Mil. Therefore, Daiichinkyo Co's market cap for the quarter that ended in Mar. 2024 was 円9,125,383 Mil.
Daiichinkyo Co's quarterly market cap
declined
from Sep. 2023 (円7,872,598 Mil) to Dec. 2023 (円7,423,940 Mil) but then
increased
from Dec. 2023 (円7,423,940 Mil) to Mar. 2024 (円9,125,383 Mil).
Daiichinkyo Co's annual market cap
increased
from Mar. 2022 (円5,136,997 Mil) to Mar. 2023 (円9,245,413 Mil) but then
declined
from Mar. 2023 (円9,245,413 Mil) to Mar. 2024 (円9,125,383 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Daiichinkyo Co's Enterprise Value for Today is 円8,484,181 Mil.
Daiichinkyo Co Market Cap Historical Data
The historical data trend for Daiichinkyo Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Daiichinkyo Co's Market Cap
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Market Cap falls into.
Daiichinkyo Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Daiichinkyo Co's Market Cap for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (TSE:4568) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Daiichinkyo Co Market Cap Related Terms
Thank you for viewing the detailed overview of Daiichinkyo Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4568 has been successfully added to your 